SCHEMBL4801283

SCHEMBL4801283

CC#CCOS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.44
CYP2D6 P10635 2/20 0.44
ADAM17 P78536 8/20 0.42
GAA P10253 1/20 0.42
STAT3 P40763 1/20 0.41
MMP2 P08253 3/20 0.40
MMP8 P22894 3/20 0.40
MMP13 P45452 3/20 0.40
ALDH1A1 P00352 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
MMP9 P14780 1/20 0.40
G6PD P11413 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA3 P07451 1/20 0.39
CA6 P23280 1/20 0.39
CA5A P35218 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7644858 0.91 GAA (0.46) CYP1A2CYP2D6GAASTAT3ALDH1A1
SCHEMBL542839 0.87 GAA (0.43) CYP1A2CYP2D6GAASTAT3ALDH1A1
SCHEMBL17643607 0.84 ALDH1A1 (0.42) CYP1A2CYP2D6ADAM17GAASTAT3
SCHEMBL1603835 0.84 GAA (0.41) CYP1A2CYP2D6GAASTAT3ALDH1A1
SCHEMBL16344942 0.84 GAA (0.41) CYP1A2CYP2D6GAASTAT3ALDH1A1
SCHEMBL7457487 0.84 GAA (0.41) CYP1A2CYP2D6GAASTAT3ALDH1A1
SCHEMBL7456678 0.84 GAA (0.41) CYP1A2CYP2D6GAASTAT3ALDH1A1
SCHEMBL576704 0.84 PSIP1 (0.41) ADAM17MMP2MMP8MMP13ALDH1A1
SCHEMBL7581349 0.83 CA12 (0.50) GAASTAT3MMP2MMP13ALDH1A1
SCHEMBL18934374 0.83 CA12 (0.50) GAASTAT3MMP2MMP13ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10066152-B2 Crosslinkable proppant particulates for use in subterranean formation operations HALLIBURTON ENERGY SERVICES, INC. (US) 2018-09-04 US claimed
US-20170198208-A1 Crosslinkable Proppant Particulates For Use In Subterranean Formation Operations HALLIBURTON ENERGY SERVICES, INC. (US) 2017-07-13 US claimed
WO-2016025002-A1 CROSSLINKABLE PROPPANT PARTICULATES FOR USE IN SUBTERRANEAN FORMATION OPERATIONS HALLIBURTON ENERGY SERVICES, INC. (US) 2016-02-18 WO claimed
US-20150086976-A1 SELF-CATALYTIC REACTION BASED ASSAY UTAH STATE UNIVERSITY (US) 2015-03-26 US claimed
US-20130059210-A1 ELECTROLYTE FOR RECHARGEABLE LITHIUM BATTERY AND RECHARGEABLE LITHIUM BATTERY INCLUDING SAME SAMSUNG SDI CO., LTD. (KR) 2013-03-07 US claimed
EP-3696901-B1 LITHIUM SECONDARY BATTERY SAMSUNG SDI CO LTD (KR) 2025-03-26 EP disclosed
CN-118894868-A Prins reactions and compounds useful for the synthesis of halichondrin macrolides and analogs thereof 卫材R&D管理有限公司 2024-11-05 CN disclosed
CN-111868044-B Prins reactions and compounds useful for the synthesis of halichondrin macrolides and analogs thereof 卫材R&D管理有限公司 2024-07-19 CN disclosed
EP-3737673-B1 PROCESS FOR PREPARING HALICHONDRIN MACROLIDES AND ANALOGS THEREOF BY A PRINS REACTION, AND INTERMEDIATES OF THIS PROCESS EISAI R&D MAN CO LTD (JP) 2024-03-06 EP disclosed
US-20230151022-A1 PRINS REACTION AND COMPOUNDS USEFUL IN THE SYNTHESIS OF HALICHONDRIN MACROLIDES AND ANALOGS THEREOF EISAI R&D MANAGEMENT CO, LTD. (JP) 2023-05-18 US disclosed
US-11542269-B2 Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-01-03 US disclosed
CN-109280075-B Peptide amide compound, preparation method and medical application thereof 四川海思科制药有限公司 2022-05-20 CN disclosed
WO-1997013752-A1 THERMALLY STABLE HINDERED AMINES AS STABILIZERS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 1997-04-17 WO disclosed
EP-0674623-A1 BICYCLIC FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1995-10-04 EP disclosed
EP-0659735-A1 PROCESS FOR PRODUCING ANILINE DERIVATIVE SAGAMI CHEMICAL RESEARCH CENTER (JP) 1995-06-28 EP disclosed
WO-1994014776-A2 BICYCLIC FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1994-07-07 WO disclosed
EP-0003883-B1 AMINO-DIBENZOPYRANS, THEIR PREPARATION, FORMULATIONS CONTAINING THEM AND THEIR USE AS PHARMACEUTICALS ELI LILLY AND COMPANY (US) 1982-10-06 EP disclosed
US-4195025-A 9-Amino-dibenzopyrans ELI LILLY AND COMPANY (US) 1980-03-25 US disclosed
EP-0003883-A1 Amino-dibenzopyrans, their preparation, formulations containing them and their use as pharmaceuticals ELI LILLY AND COMPANY (US) 1979-09-05 EP disclosed
US-4152450-A 9-Amino-dibenzopyrans ELI LILLY AND COMPANY (US) 1979-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151022-A1 PRINS REACTION AND COMPOUNDS USEFUL IN THE SYNTHESIS OF HALICHONDRIN MACROLIDES AND ANALOGS THEREOF LSS, DHPS, COASY CYP1A2 1194/4885CYP2D6 2590/4885ADAM17 2572/4885
US-11542269-B2 Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof LSS, DHPS, COASY CYP1A2 1194/4885CYP2D6 2590/4885ADAM17 2572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.